Bezuclastinib
- Generic Name
- Bezuclastinib
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17N5O
- CAS Number
- 1616385-51-3
- Unique Ingredient Identifier
- 2ROQ545LAG
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Cogent Biosciences, Inc.
- Registration Number
- NCT06948955
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
- Conditions
- Systemic Mastocytoses, IndolentSystemic Mastocytoses, Aggressive
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Cogent Biosciences, Inc.
- Registration Number
- NCT06915766
SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST
- Conditions
- Gastrointestinal Stromal TumorsGIST
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-01-31
- Target Recruit Count
- 40
- Registration Number
- NCT06208748
- Locations
- πΊπΈ
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈOregon Health & Science University, Portland, Oregon, United States
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- Conditions
- Advanced Gastrointestinal Stromal TumorsMetastatic Cancer
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 442
- Registration Number
- NCT05208047
- Locations
- π¬π§
Royal Marsden Hospital - Surrey, London, United Kingdom
π§π·lnstituto Nacional de Cancer - INCA, Rio De Janeiro, Brazil
π¨π±Centro de Oncologia de Precision, Universidad Mayor, Santiago, Chile
(Summit) a Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients with Indolent or Smoldering Systemic Mastocytosis
- Conditions
- SSMMastocytosis, IndolentMastocytosis, SystemicMastocytosisISMBMMSmoldering Systemic MastocytosisBone Marrow Mastocytosis
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT05186753
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈMayo Clinic Arizona, Phoenix, Arizona, United States
πΊπΈOne of a Kind Clinical Research Center, Scottsdale, Arizona, United States
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Conditions
- Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)Aggressive Systemic Mastocytosis (ASM)
- Interventions
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04996875
- Locations
- πΊπΈ
University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
πΊπΈMayo Clinic Arizona, Phoenix, Arizona, United States
πΊπΈCity of Hope Comprehensive Cancer Center, Duarte, California, United States
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02401815
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈOSU Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.